Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi- 110062, India.
Department of Pharmacology, Pharmaceutical Medicine, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi-110062, India.
Curr Top Med Chem. 2020;20(20):1839-1854. doi: 10.2174/1568026620666200624161801.
Liver cancer, being the utmost prevalent fatal malignancy worldwide, is ranked as the fifth leading cause of deaths associated with cancer. Patients with liver cancer are diagnosed often at an advanced stage, contributing to poor prognosis. Of all forms of liver cancer, hepatocellular carcinoma (HCC) contributes to 90% of cases, with chemotherapy being the treatment of choice. However, unfavorable toxicity of chemotherapy drugs and the vulnerability of nucleic acid-based drugs to degradation, have limited their application in clinical settings. So, in order to improvise their therapeutic efficacy in HCC treatment, various nanocarrier drug delivery systems have been explored. Furthermore, nanoparticle based imaging provides valuable means of accurately diagnosing HCC. Thus, in recent years, the advent of nanomedicine has shown great potential and progress in dramatically altering the approach to the diagnosis as well as treatment of liver cancer. Nanoparticles (NPs) are being explored as potential drug carriers for small molecules, miRNAs, and therapeutic genes used for liver cancer treatment. This review emphasizes on the current developments and applications of nanomedicine based therapeutic and diagnostic approaches in HCC.
肝癌是全球最常见的致命恶性肿瘤，位居癌症相关死亡的第五大主要原因。肝癌患者常常在晚期被诊断出来，导致预后不良。在所有类型的肝癌中，肝细胞癌 (HCC) 占 90%，化疗是首选治疗方法。然而，化疗药物的不良毒性和基于核酸的药物易降解限制了它们在临床中的应用。因此，为了提高 HCC 治疗的疗效，已经探索了各种纳米载体药物传递系统。此外，基于纳米颗粒的成像为准确诊断 HCC 提供了有价值的手段。因此，近年来，纳米医学的出现显示出了巨大的潜力和进展，极大地改变了肝癌的诊断和治疗方法。纳米颗粒 (NPs) 被探索用作小分子、miRNAs 和治疗基因的潜在药物载体，用于肝癌治疗。本文重点介绍了基于纳米医学的治疗和诊断方法在 HCC 中的最新进展和应用。
